Dapagliflozin regulates chondrocyte homeostasis and protects against osteoarthritis via targets AMPKα and SGLT2 - PubMed
5 hours ago
- #AMPKα
- #Dapagliflozin
- #osteoarthritis
- Dapagliflozin (DAPA) shows therapeutic potential for osteoarthritis (OA) by regulating chondrocyte homeostasis.
- DAPA protects cartilage in OA patients and surgically induced OA models in mice.
- DAPA restores chondrocyte metabolic homeostasis by activating the AMPK signaling pathway and suppressing MAPK signaling.
- AMPKα is identified as a novel target of DAPA, which alleviates excessive catabolism and promotes anabolic processes.
- DAPA also targets SGLT2, rescuing impaired autophagy in degenerated chondrocytes.
- The study highlights the therapeutic promise of combined AMPK activation and SGLT2 inhibition in OA treatment.